复发性CBT的化学放射治疗案例报告
Guangyu Liu1,2, Shuangyan Zhao1,2, Jiankai Wang2
1Gansu University of Chinese Medicine, No. 35, Dingxi East Road, 730000, Lanzhou, China.
Discover oncology
|August 11, 2025
概括
循环性动脉体瘤 (CBTs) 可能具有挑战性. 这一案例表明,化疗放射治疗 (IGRT和CVD化疗) 可以成为复杂复发的可行救援选择.
科学领域:
- 在瘤学瘤学.
- 神经外科 神经外科
背景情况:
- 状体瘤 (CBT) 是一种罕见的偏瘤,通常通过手术治疗.
- 术后的CBT复发是一个重大的临床挑战.
研究的目的:
- 为了呈现一种以多模式方法管理的复发性动脉体瘤病例.
- 评估化疗放射治疗作为解剖学复杂的复发性CBT的救援治疗的疗效.
主要方法:
- 一名49岁的女性患有复发性CBT,涉及甲孔,接受了治疗.
- 治疗包括图像导向放射治疗 (IGRT) 和4轮心血管疾病化疗.
- 通过使用RECIST标准来评估反应.
主要成果:
- 患者在治疗后实现了疾病稳定.
- 这一结果支持在精选的复发性CBT病例中使用化疗放射治疗.
结论:
- 多式疗法,包括化疗和放射疗法,可以有效治疗复发性CBT.
- 需要进一步的研究和标准化的协议来验证这种方法对复杂的复发.
相关概念视频
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K


